Physician profile
Robert Lindsay
NPI 1144383043
$3,721.17
in general payments reported to CMS, 2019-2025
34 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $51.29 · 2021: $279 · 2022: $820 · 2023: $787 · 2024: $443 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $771.73 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $484.05 | 2019-2024 | |
| Novo Nordisk INC | $431.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $287.14 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.99 | 2019-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $152.24 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $137.42 | 2019-2022 | |
| Astellas Pharma US INC | $124.01 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $115.87 | 2019-2023 | |
| Abbott Laboratories | $103.17 | 2019-2025 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $91.57 | 2021-2024 | |
| Amarin Pharma, INC. | $77.59 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $76.81 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $68.87 | 2022-2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $58.67 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.34 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $51.27 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $42.02 | 2019-2020 | |
| Exact Sciences Corporation | $38.97 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $27.50 | 2022 | |
| Dexcom, INC. | $26.38 | 2022-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $23.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.06 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.14 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.69 | 2022 | |
| Glaxosmithkline, LLC. | $15.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.71 | 2019 | |
| Radius Health, INC. | $15.53 | 2019 | |
| Shire North American Group INC | $13.37 | 2019 | |
| Sanofi Pasteur INC. | $13.26 | 2022 | |
| Bioventus LLC | $11.87 | 2019 | |
| Bsn Medical INC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.